Abstract
The plasma protein binding ability of cis-diammine-{[bis(phosphonatomethyl)amino]acetato(2–)-O1, N1}platinum(II)(DBP), a tumour-inhibiting platinum phosphonato compound with osteotropic properties, was compared with that of the well established anticancer drug cisplatin (CDDP). The separation of the plasma protein-platinum adducts was performed by a fractionated ultrafiltration experiment. The platinum levels in the protein fraction and the ultrafiltrate of the blood plasma were detected with an échelle-based ICP-OES system with an ultrasonic nebulizer (USN) and by ETAAS with Zeeman-effect background correction. The over-all performance of ETAAS was better than that of ICP-OES. Owing to strong, protein-induced matrix effects in the USN, the ICP-OES measurements resulted in lower platinum levels in the protein fraction of blood. In the determination of platinum in the ultrafiltrate, both systems showed good performance. In comparison with CDDP, DBP shows a significant tendency to bind to plasma proteins of lower molecular mass.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
